Harnessing world-leading microRNA technologies to deliver game-changing applications that save and improve lives.
Founded on pioneering research and tech
MiRXES is a global leader in delivering liquid biopsy solutions for early cancer detection.
Go to Technology Page
Delivering real solutions powered by innovation
Early Cancer Detection Solutions
microRNA Research Solutions
Leading a global ecosystem supporting early cancer detection and management
Research Collaborations and Services
Tech Investments and Partnerships
A*STAR Scientist-Entrepreneur Award 2017
MiRXES co-founders Prof Too Heng-Phon, Dr Zhou Lihan, and Dr Zou Ruiyang receiving the award from A*STAR Chairman Lim Chuan Poh.
Most Promising Startup, Emerging Enterprise Award 2016
MiRXES co-founder and chairman Prof Too Heng-Phon receiving the award from Senior Minister of State for Trade and Industry Dr Koh Poh Koon.
7/11/2019 - MiRXES featured in Business Times article on getting timely guidance from Pro-Enterprise Panel.
3/6/2019 - Gastric cancer clinical study presented at ASCO Annual Meeting
18/5/2019 - Community screening project launched with #CHECKED Movement.
11/4/2019 - Asia-Pacific Biotech News interviews co-founders.
25/2/2019 - CIO Asia interviews MiRXES CTO Zou Ruiyang.
26/6/2018 - Beth Israel Deaconess Medical Center to adopt MiRXES tech.
5/1/2018 - Lung cancer collaboration with J&J Innovation and Janssen announced.
18/9/2019 - Gastric cancer test and MiRXES journey reported in the South China Morning Post.
1/6/2019 - Breast cancer research presented at ASCO Annual Meeting
9/5/2019 - GASTROClear test kit approved by Singapore's Health Science Authority.
3/4/2019 - Gastric cancer test and clinical collaborator featured in Straits Times.
27/11/2018 - MiRXES and Venturecraft merge under the Ark Bio umbrella.
14/4/2018 - Lung cancer research presented at AACR Annual Meeting.